Ingredient or product comparison
Lose Face Fat with Peptides: Protocol Comparison
CJC-1295/Ipamorelin (injectable) Pulsatile GH release → HSL activation → lipolysis in all subcutaneous depots including facial fat 100–200 mcg each peptide, subcutaneous, before bed 8–12 weeks with moderate caloric deficit Mimics natural GH pulse; preserves en
This source-based comparison does not add ratings or recommend a winner.
- CJC-1295/Ipamorelin (injectable)
- Pulsatile GH release → HSL activation → lipolysis in all subcutaneous depots including facial fat
- 100–200 mcg each peptide, subcutaneous, before bed
- 8–12 weeks with moderate caloric deficit
- Mimics natural GH pulse; preserves endogenous production; no cortisol/prolactin spike
- Requires nightly injections; results contingent on caloric deficit
- MK-677 (oral)
- Sustained ghrelin receptor agonism → chronic GH elevation
- 12.5–25 mg oral, before bed
- 10–14 weeks (slower than pulsatile protocols)
- Oral administration; sustained 24-hour GH elevation
- Less effective for acute lipolysis; increases appetite via ghrelin mimicry
- Exogenous GH (pharmaceutical)
- Direct GH receptor binding → immediate HSL activation
- 2–4 IU daily, subcutaneous
- 6–10 weeks
- Strongest lipolytic signal; dose-controllable
- Suppresses endogenous GH production; expensive; requires prescription
- Dietary restriction alone (no peptides)
- Caloric deficit → reduced insulin → passive lipolysis
- N/A. 500 kcal/day deficit standard
- 12–16 weeks (highly variable)
- No cost; no injections
- Triggers metabolic adaptation (reduced NEAT, leptin suppression); high failure rate long-term